Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
IMPROVED SILK FIBERS
Document Type and Number:
WIPO Patent Application WO/2016/149414
Kind Code:
A1
Abstract:
Methods and compositions are provided for improved proteinaceous block copolymer fibers based on long repeat units having molecular weight of greater than about 10 kDal. Each repeat unit includes more than about 150 amino acid residues that are organized into a number of "quasi -repeat units." The fibers have improved mechanical properties that better recapitulate those of the native silk fibers.

Inventors:
BRESLAUER DAVID (US)
WRAY LINDSAY (US)
KITTLESON JOSHUA (US)
Application Number:
PCT/US2016/022707
Publication Date:
September 22, 2016
Filing Date:
March 16, 2016
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
BOLT THREADS INC (US)
International Classes:
C12P21/02; C07K14/435
Domestic Patent References:
WO2012055854A12012-05-03
WO2014037453A12014-03-13
WO2011113592A12011-09-22
WO2010015419A22010-02-11
Foreign References:
US20120041177A12012-02-16
US20140194603A12014-07-10
US20070260039A12007-11-08
US20150047532A12015-02-19
Other References:
See also references of EP 3271471A4
Attorney, Agent or Firm:
SHUSTER, Michael, J. et al. (Silicon Valley Center801 California Stree, Mountain View CA, US)
Download PDF:
Claims:
What is claimed is:

1. A proteinaceous block copolymer fiber, wherein the block copolymer

comprises: at least two occurrences of a repeat unit, the repeat unit comprising: more than 150 amino acid residues and having a molecular weight of at least lOkDal; an alanine-rich region with 6 or more consecutive amino acids,

comprising an alanine content of at least 80%; a glycine-rich region with 12 or more consecutive amino acids,

comprising a glycine content of at least 40% and an alanine content of less than 30%; and wherein the fiber comprises at least one property selected from the group consisting of a modulus of elasticity greater than 550 cN/tex, an extensibility of at least 10% and an ultimate tensile strength of at least 15 cN/tex.

2. The fiber of claim 1, wherein the repeat unit comprises from 150 to 1000 amino acid residues.

3. The fiber of any of claims 1-2, wherein the repeat unit has a molecular weight from lO kDal to 100 kDal.

4. The fiber of any of claims 1-3, wherein the repeat comprises from 2 to 20 alanine-rich regions.

5. The fiber of any of claims 1-4, wherein each alanine-rich region comprises from 6 to 20 consecutive amino acids, comprising an alanine content from 80% to 100%.

6. The fiber of any of claims 1-5, wherein the repeat comprises from 2 to 20 glycine-rich regions.

7. The fiber of any of claims 1-6, wherein each glycine-rich region comprises from 12 to 150 consecutive amino acids, comprising a glycine content from 40% to 80%.

8. The fiber of claim 1, wherein the repeat unit comprises 315 amino acid

residues, 6 alanine-rich regions, and 6 glycine-rich regions,

wherein the alanine-rich regions comprise from 7 to 9 consecutive amino acids, and alanine content of 100%, and

wherein the glycine-rich regions comprise from 30 to 70 consecutive amino acids, and glycine content from 40 to 55%.

9. The fiber of any of claims 1-8, wherein the modulus of elasticity is from

550 cN/tex to 1000 cN/tex.

10. The fiber of any one of claims 1-9, wherein the extensibility is from 10% to

20%.

11. The fiber of any one of claims 1-10, wherein the ultimate tensile strength is from 15 cN/tex to 100 cN/tex.

12. The fiber of any one of claims 1-11, wherein the modulus of elasticity is greater than 550 cN/tex.

13. The fiber of any one of claims 1-12, wherein the extensibility is at least 10%.

14. The fiber of any one of claims 1-13, wherein the ultimate tensile strength is at least 15 cN/tex.

15. The fiber of any one of claims 1-14, wherein the modulus of elasticity is greater than 550 cN/tex, the extensibility is at least 10%, and ultimate tensile strength is at least 15 cN/tex.

16. The fiber of any one of claims 1-15, wherein each repeat unit has at least 95% sequence identity to a sequence that comprises from 2 to 20 quasi-repeat units, each quasi-repeat unit having a composition comprising {GGY-[GPG-Xi]ni- GPS-(A)„2 } , wherein for each quasi-repeat unit:

X1 is independently selected from the group consisting of SGGQQ, GAGQQ, GQGPY, AGQQ, and SQ; and nl is from 4 to 8, and n2 is from 6 to 10.

17. The fiber of claim 16, wherein nl is from 4 to 5 for at least half of the quasi- repeat units.

18. The fiber of any one of claims 16-17, wherein n2 is from 5 to 8 for at least half of the quasi-repeat units.

19. The fiber of any one of claims 1-18, wherein a quasi repeat unit has at least

95% sequence identity to a MaSp2 dragline silk protein sequence.

20. The fiber of any one of claims 1-19, wherein: the poly-alanine regions form a plurality of nanocrystalline beta-sheets; and the glycine-rich regions form a plurality of beta-turn structures.

21. The fiber of any one of claims 1-20, wherein the repeat unit of the

proteinaceous block copolymer comprises SEQ ID NO: 1.

22. A method of synthesizing a proteinaceous block copolymer fiber, the method comprising: expressing a block copolymer polypeptide wherein the block

copolymer comprises at least two repeat units, each repeat unit comprising: more than 150 amino acid residues and having a molecular weight of at least 20kDal; an alanine-rich region with 6 or more consecutive amino acids, comprising an alanine content of at least 80%; and a glycine-rich region with 12 or more consecutive amino acids, comprising a glycine content of at least 40% and an alanine content of less than 30%; formulating a spin dope comprising the expressed polypeptide and at least one solvent; and extruding the spin dope through a spinneret and through at least one coagulation bath to form the fiber, wherein the fiber comprises a property selected from the group consisting of a modulus of elasticity greater than 400 cN/tex, an extensibility of at least 10% and an ultimate tensile strength of at least 15 cN/tex.

23. The fiber of claim 22, wherein the repeat unit comprises from 150 to 1000 amino acid residues.

24. The fiber of any one of claims 22-23, wherein the repeat unit has a molecular weight from 10 to 100 kDal.

25. The fiber of any one of claims 22-24, wherein the repeat comprises from 2 to

20 alanine-rich regions.

26. The fiber of any one of claims 22-25, wherein each alanine-rich region comprises from 6 to 20 consecutive amino acids, comprising an alanine content from 80% to 100%.

27. The fiber of any one of claims 22-26, wherein the repeat comprises from 2 to

20 glycine-rich regions.

28. The fiber of any one of claims 22-27, wherein each glycine-rich region

comprises from 12 to 150 consecutive amino acids, comprising a glycine content from 40% to 80%.

29. The fiber of claim 22, wherein the repeat unit comprises 315 amino acid

residues, 6 alanine-rich regions, and 6 glycine-rich regions,

wherein the alanine-rich regions comprise from 7 to 9 consecutive amino acids, and alanine content of 100%, and

wherein the glycine-rich regions comprise from 30 to 70 consecutive amino acids, and glycine content from 40 to 55%.

30. The method of any one of claims 22-29, wherein the fiber modulus of elasticity is from 550 cN/tex to 575 cN/tex.

31. The method of any one of claims 22-30, wherein the fiber extensibility is from 10% to 20%.

32. The method of any one of claims 22-31, wherein the fiber ultimate tensile strength from 15 cN/tex to 20 cN/tex.

33. The method of any one of claims 22-32, wherein the fiber modulus of elasticity is greater than 400 cN/tex.

34. The method of any one of claims 22-33, wherein the fiber extensibility is at least 10%.

35. The method of any one of claims 22-34, wherein the fiber ultimate tensile

strength is at least 15 cN/tex.

36. The method of any one of claims 22-35, wherein the fiber modulus of elasticity is greater than 400 cN/tex, the extensibility is at least 10%, and the ultimate tensile strength is at least 15 cN/tex.

37. The method of any one of claims 22-36, wherein extruding the fiber through at least one coagulation bath comprises extruding the fiber sequentially through a first coagulation bath and a second bath, the first coagulation bath having a first chemical composition and the second bath having a second chemical composition different from the first chemical composition.

38. The method of claim 37, wherein: the first chemical composition comprises a first solvent and at least one of a first acid and a first salt; and the second chemical composition comprises a second solvent and at least one of a second acid and a second salt; wherein the concentration of the second solvent is higher than the concentration of the first solvent.

39. The method of claim 38, wherein the first solvent and the second solvent are the same.

40. The method of claim 38, wherein the first solvent and the second solvent are different.

41. The method of any one of claims 38-40, wherein the first acid and the second acid are the same.

42. The method of any one of claims 38-40, wherein the first acid and the second acid are different.

43. The method of any one of claims 22-42, wherein the fiber is translucent in the first coagulation bath.

44. The method of any one of claims 22-43, wherein a quasi repeat unit has at least

95% sequence identity to a MaSp2 dragline silk protein sequence.

45. The method of any one of claims 22-44, wherein the repeat unit of the block copolymer comprises SEQ ID NO: 1.

Description:
IMPROVED SILK FIBERS

RELATED APPLICATION DATA

[0001] This application claims the benefit of U.S. Provisional Application Serial No.

62/133,895, filed March 16, 2015, the entire disclosure of which is incorporated by reference for all purposes.

TECHNICAL FIELD

[0002] The present disclosure relates generally to silk fibers produced from spider silk proteins. Specifically, the present disclosure relates to improved spider silk proteins.

BACKGROUND

[0003] Polymeric fibers synthesized from the polypeptides in spider silks are not

commercially available due to the difficulty in commercial scale fabrication and the technical challenges in producing fibers that are manufacturable into threads, yarns, or other fibers.

[0004] Natural spider silk proteins are large (>150kDa, >1000 amino acids) polypeptides divisible into three domains: an N-terminal non-repetitive domain (NTD), a repeat domain (REP), and a C-terminal non-repetitive domain (CTD). The repeat domain comprises approximately 90% of the natural polypeptide, while the NTD and CTD are relatively small (-150, -100 amino acids respectively). The NTD and CTD are well-studied and are believed to confer to the entire polypeptide chain aqueous stability, pH sensitivity, and molecular alignment upon aggregation.

[0005] A single species of spider creates a variety of fibers, each of which is utilized for different functions. Examples of these different functions include draglines, web capture spirals, prey immobilization, and silks to protect an egg sac. Dragline silks have exceptional mechanical properties. They are very strong for their weight and diameters, and also exhibit a combination of high extensibility in conjunction with high ultimate tensile strength.

[0006] Amino acid composition and protein structure vary considerably between types of silks and species of spiders. For example, orb weaving spiders have six unique types of glands that produce different silk polypeptide sequences that are polymerized into fibers tailored to fit an environmental or lifecycle niche. The fibers are named for the gland they originate from and the polypeptides are labeled with the gland abbreviation, for example "Sp" for spidroin (short for spider fibroin). In orb weaver spiders, examples include Major Ampullate (MaSp, also called dragline), Minor Ampullate (MiSp), Flagelliform (Flag), Aciniform (AcSp), Tubuliform (TuSp), and Pyriform (PySp).

[0007] There is a common class of orb weaver MaSp dragline silks (e.g. Nephila clavipes MaSpl) where the repeat domains contain glycine-rich regions, which are associated with amorphous regions of the fiber (possibly containing alpha-helices and/or beta-turns), and poly-alanine regions, which are associated with the beta-sheet crystalline regions of the fiber. The amino acid composition and sequence, as well as the fiber formation details both affect the mechanical properties of the fiber.

[0008] While it is thought that commercial applications of spider silk are possible, spider silk cannot be commercially farmed and harvested in the same way that silkworm silk is. This is due, in part, to the aggressive and territorial nature of spiders. Therefore, synthetically produced spider silk is thought to be the most likely cost-effective and viable path to commercialization.

[0009] Currently, recombinant silk fibers are not commercially available and, with a handful of exceptions, are not produced in microorganisms outside of Escherichia coli and other gram-negative prokaryotes. Recombinant silks produced to date have largely consisted either of polymerized short silk sequence motifs or fragments of native repeat domains, sometimes in combination with NTDs and/or CTDs. While these methods are able to produce small scales of recombinant silk polypeptides (milligrams at lab scale, kilograms at bioprocessing scale) using intracellular expression and purification by chromatography or bulk precipitation, they have not scaled to match conventional textile fibers. Additional production hosts that have been utilized to make silk polypeptides include transgenic goats, transgenic silkworms, and plants. Similarly, these hosts have yet to enable commercial scale production of silk, presumably due to slow engineering cycles.

[0010] What is needed, therefore, are improved spider-silk derived recombinant protein designs, expression constructs for their production at high rates, microorganisms expressing these proteins, and synthetic fibers made from these proteins that exhibit many of the desirable mechanical and morphological properties of natural spider silk fibers.

SUMMARY

[0011] In some embodiments the invention provides a proteinaceous block copolymer fiber, wherein the block copolymer comprises: at least two occurrences of a repeat unit, the repeat unit comprising: more than 150 amino acid residues and having a molecular weight of at least lOkDal; an alanine-rich region with 6 or more consecutive amino acids, comprising an alanine content of at least 80%; a glycine-rich region with 12 or more consecutive amino acids, comprising a glycine content of at least 40% and an alanine content of less than 30%; and wherein the fiber comprises at least one property selected from the group consisting of a modulus of elasticity greater than 550 cN/tex, an extensibility of at least 10% and an ultimate tensile strength of at least 15 cN/tex.

[0012] In some embodiments, the repeat unit comprises from 150 to 1000 amino acid residues. In some embodiments, the repeat unit has a molecular weight from 10 kDal to 100 kDal.

[0013] In some embodiments, the repeat comprises from 2 to 20 alanine-rich regions. [0014] In some embodiments, each alanine-rich region comprises from 6 to 20 consecutive amino acids, comprising an alanine content from 80% to 100%.

[0015] In some embodiments, the repeat comprises from 2 to 20 glycine-rich regions.

[0016] In some embodiments, each glycine-rich region comprises from 12 to 150 consecutive amino acids, comprising a glycine content from 40% to 80%.

[0017] In some embodiments, the modulus of elasticity is from 550 cN/tex to 1000 cN/tex.

[0018] In some embodiments, the extensibility is from 10% to 20%.

[0019] In some embodiments, the ultimate tensile strength is from 15 cN/tex to 100 cN/tex.

[0020] In some embodiments, the modulus of elasticity is greater than 550 cN/tex.

[0021] In some embodiments, the extensibility is at least 10%.

[0022] In some embodiments, the ultimate tensile strength is at least 15 cN/tex.

[0023] In some embodiments, the modulus of elasticity is greater than 550 cN/tex, the extensibility is at least 10%, and ultimate tensile strength is at least 15 cN/tex.

[0024] In some embodiments, each repeat unit has at least 95% sequence identity to a sequence that comprises from 2 to 20 quasi-repeat units, each quasi-repeat unit having a composition comprising {GGY-[GPG-Xl]nl-GPS-(A)n2}, wherein for each quasi-repeat unit: XI is independently selected from the group consisting of SGGQQ, GAGQQ, GQGPY, AGQQ, and SQ; and nl is from 4 to 8, and n2 is from 6 to 10.

[0025] In some embodiments, a quasi repeat unit has at least 95% sequence identity to a MaSp2 dragline silk protein sequence.

[0026] In some embodiments, the invention provides for methods of synthesizing a proteinaceous block copolymer fiber by expressing a block copolymer of the present invention, formulating a spin dope comprising the expressed polypeptide and at least one solvent; and extruding the spin dope through a spinneret and through at least one coagulation bath to form the fiber, wherein the fiber comprises a property selected from the group consisting of a modulus of elasticity greater than 400 cN/tex, an extensibility of at least 10% and an ultimate tensile strength of at least 15 cN/tex.

[0027] In some embodiments, extruding the fiber through at least one coagulation bath comprises extruding the fiber sequentially through a first coagulation bath and a second bath, the first coagulation bath having a first chemical composition and the second bath having a second chemical composition different from the first chemical composition.

[0028] In some embodiments, the first chemical composition comprises a first solvent and at least one of a first acid and a first salt; and the second chemical composition comprises a second solvent and at least one of a second acid and a second salt; wherein the concentration of the second solvent is higher than the concentration of the first solvent, and wherein the first and second solvents are the same or different, and the first and second acids are the same or different.

[0029] In some embodiments, the fiber is translucent in the first coagulation bath.

BRIEF DESCRIPTION OF THE DRAWINGS

[0030] FIG. 1 schematically illustrates a molecular structure of a block copolymer of the present disclosure, in an embodiment.

[0031] FIG. 2 is a magnified image of a fiber of the present disclosure having hollow core, in an embodiment.

[0032] FIG. 3 is a magnified image of a fiber of the present disclosure having a corrugated surface, in an embodiment.

[0033] FIGS. 4A-4D show mechanical properties measured from a plurality of fibers of the present disclosure, in embodiments.

[0034] FIG. 5 is a first stress-strain curve measured from a fiber of the present disclosure, in an embodiment. [0035] FIG. 6 is a second stress-strain curve measured from a fiber of the present disclosure, in an embodiment.

[0036] FIG. 7 is a set of stress-strain curves measured from a fiber of the present disclosure, in an embodiment.

[0037] The figures depict various embodiments of the present disclosure for purposes of illustration only. One skilled in the art will readily recognize from the following discussion that alternative embodiments of the structures and methods illustrated herein may be employed without departing from the principles described herein.

DETAILED DESCRIPTION

OVERVIEW

[0038] Embodiments of the present disclosure include fibers synthesized from proteinaceous copolymers of recombinant spider silk proteins derived from MaSp2, such as from the species Argiope bruennichi . Each synthesized fiber contains protein molecules that include two to twenty repeat units, in which a molecular weight of each repeat unit is greater than about 20 kDal. Within each repeat unit of the copolymer are more than about 60 amino acid residues that are organized into a number of "quasi-repeat units." In some embodiments, the repeat unit of a polypeptide described in this disclosure has at least 95% sequence identity to a MaSp2 dragline silk protein sequence.

[0039] Utilizing long polypeptides with fewer long exact repeat units has many advantages over utilizing polypeptides with a greater number of shorter exact repeat units to create a recombinant spider silk fiber. An important distinction is that a "long exact repeat" is defined as an amino acid sequence without shorter exact repeats concatenated within it. Long polypeptides with long exact repeats are more easily processed than long polypeptides with a greater number of short repeats because they suffer less from homologous recombination causing DNA fragmentation, they provide more control over the composition of amorphous versus crystalline domains, as well as the average size and size distribution of the nano- crystalline domains, and they do not suffer from unwanted crystallization during intermediate processing steps prior to fiber formation. Throughout this disclosure the term "repeat unit" refers to a subsequence that is exactly repeated within a larger sequence.

[0040] Throughout this disclosure, wherever a range of values is recited, that range includes every value falling within the range, as if written out explicitly, and further includes the values bounding the range. Thus, a range of "from X to Y" includes every value falling between X and Y, and includes X and Y.

[0041] The term percent "identity," in the context of two or more nucleic acid or polypeptide sequences, refer to two or more sequences or subsequences that have a specified percentage of nucleotides or amino acid residues that are the same, when compared and aligned for maximum correspondence, as measured using one of the sequence comparison algorithms described below (e.g., BLASTP and BLASTN or other algorithms available to persons of skill) or by visual inspection. Depending on the application, the percent "identity" can exist over a region of the sequence being compared, e.g., over a functional domain, or, alternatively, exist over the full length of the two sequences to be compared. Within this disclosure, a "region" is considered to be 6 or more amino acids in a continuous stretch within a polypeptide.

[0042] For sequence comparison, typically one sequence acts as a reference sequence to which test sequences are compared. When using a sequence comparison algorithm, test and reference sequences are input into a computer, subsequence coordinates are designated, if necessary, and sequence algorithm program parameters are designated. The sequence comparison algorithm then calculates the percent sequence identity for the test sequence(s) relative to the reference sequence, based on the designated program parameters. [0043] Optimal alignment of sequences for comparison can be conducted, e.g., by the local homology algorithm of Smith & Waterman, Adv. Appl. Math. 2:482 (1981), by the homology alignment algorithm of Needleman & Wunsch, J. Mol. Biol. 48:443 (1970), by the search for similarity method of Pearson & Lipman, Proc. Nat'l. Acad. Sci. USA 85:2444 (1988), by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, Wis.), or by visual inspection (see generally Ausubel et al., infra).

[0044] One example of an algorithm that is suitable for determining percent sequence identity and sequence similarity is the BLAST algorithm, which is described in Altschul et al., J. Mol. Biol. 215:403-410 (1990). Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information. Such software also can be used to determine the mole percentage of any specified amino acid found within a polypeptide sequence or within a domain of such a sequence. As the person of ordinary skill will recognize such percentages also can be determined through inspection and manual calculation.

[0045] In embodiments, the morphology of the synthesized fibers includes fibers having a hollow cross-section or a corrugated outer surface with corrugations parallel to a longitudinal axis of a fiber. In embodiments, the synthesized fibers exhibit a strain to fracture of greater than 10%, or greater than 20%, or greater than 100%, or greater than 200%, or greater than 300%), or greater than 400%). In embodiments, the synthesized fibers exhibit a strain to fracture of from 1% to 400%, or from 1 to 200%, or from 1 to 100%, or from 1 to 20%, or from 10 to 200%, or from 10 to 100%, or from 10 to 50%, or from 10 to 20%, or from 50% to 150%, or from 100% to 150%, or from 300% to 400%. In embodiments, the synthesized fibers exhibit an elastic modulus greater than 1500 MPa, or greater than 2000 MPa, or greater than 3000 MPa, or greater than 5000 MPa, or greater than 6000 MPa, or greater than 7000 MPa. In embodiments, the synthesized fibers exhibit an elastic modulus from 5200 to 7000 MPa, or from 1500 to 10000 MPa, or from 1500 to 8000 MPa, or from 2000 to 8000 MPa, or from 3000 to 8000 MPa, or from 5000 to 8000 MPa, or from 5000 to 6000 MPa, or from 6000 to 8000 MPa. In embodiments, the synthesized fibers exhibit an elastic modulus greater than 100 cN/tex, or greater than 200 cN/tex, or greater than 300 cN/tex, or greater than 400 cN/tex, or greater than 500 cN/tex, or greater than 550 cN/tex, or greater than 600 cN/tex. In embodiments, the synthesized fibers exhibit an elastic modulus from 100 to 600 cN/tex, or from 200 to 600 cN/tex, or from 300 to 600 cN/tex, or from 400 to 600 cN/tex, or from 500 to 600 cN/tex, or from 550 to 600 cN/tex, or from 550 to 575 cN/tex, or from 500 to 750 cN/tex, or from 500 to 1000 cN/tex, or from 500 to 1500 cN/tex. In embodiments, the synthesized fibers exhibit a maximum tensile strength greater than 100 MPa, or greater than 120 MPa, or greater than 140 MPa, or greater than 160 MPa, or greater than 180 MPa, or greater than 200 MPa, or greater than 220 MPa, or greater than 240 MPa, or greater than 260 MPa, or greater than 280 MPa, or greater than 300 MPa, or greater than 400 MPa, or greater than 600 MPa, or greater than 1000 MPa. In embodiments, the synthesized fibers exhibit a maximum tensile strength from 100 to 1000 MPa, or from 100 to 500 MPa, or from 100 to 300 MPa, or from 100 to 250 MPa, or from 100 to 200 MPa, or from 100 to 150 MPa. In embodiments, the synthesized fibers exhibit an ultimate tensile strength greater than 100 MPa, or greater than 120 MPa, or greater than 140 MPa, or greater than 160 MPa, or greater than 180 MPa, or greater than 200 MPa, or greater than 220 MPa, or greater than 240 MPa, or greater than 260 MPa, or greater than 260 MPa, or greater than 280 MPa, or greater than 300 MPa, or greater than 400 MPa, or greater than 600 MPa, or greater than 1000 MPa. In embodiments, the synthesized fibers exhibit an ultimate tensile strength from 100 to 1000 MPa, or from 100 to 500 MPa, or from 100 to 300 MPa, or from 100 to 250 MPa, or from 100 to 200 MPa, or from 100 to 150 MPa. In embodiments, the synthesized fibers exhibit a maximum tensile strength greater than 5 cN/tex, or greater than 10 cN/tex, or greater than 15 cN/tex, or greater than 20 cN/tex, or greater than 25 cN/tex. In embodiments, the synthesized fibers exhibit a maximum tensile strength from 5 to 30 cN/tex, or from 5 to 25 cN/tex, or from 10 to 30 cN/tex, or from 10 to 20 cN/tex, or from 15 to 20 cN/tex, or from 15 to 50 cN/tex, or from 15 to 75 cN/tex, or from 15 to 100 cN/tex. In embodiments, the synthesized fibers exhibit an ultimate tensile strength greater than 5 cN/tex, or greater than 10 cN/tex, or greater than 15 cN/tex, or greater than 20 cN/tex, or greater than 25 cN/tex. In embodiments, the synthesized fibers exhibit an ultimate tensile strength from 5 to 30 cN/tex, or from 5 to 25 cN/tex, or from 10 to 30 cN/tex, or from 10 to 20 cN/tex, or from 15 to 20 cN/tex, or from 15 to 50 cN/tex, or from 15 to 75 cN/tex, or from 15 to 100 cN/tex. In some embodiments, the synthesized fibers exhibit a work of rupture greater than 0.2 cN*cm, or greater than 0.4 cN*cm, or greater than 0.8 cN*cm, or greater than 0.9 cN*cm, or greater than 1.3 cN*cm, or greater than 2 cN*cm, or from 0.2 to 2 cN*cm, or from 0.4 to 2 cN*cm, 0.6 to 2 cN*cm, or from 0.5 to 2 cN*cm, or from 0.5 to 1.3 cN*cm, or from 0.7 to 1.1 cN*cm. In some embodiments, the synthesized fibers exhibit linear density less than 5 dtex, or less than 3 dtex, or less than 2 dtex, or less than 1.5 dtex, or greater than 1.5 dtex, or greater than 1.7 dtex, or greater than 2 dtex, or from 1 to 5 dtex, or from 1 to 3 dtex, or from 1.5 to 2 dtex, or from 1.5 to 2.5 dtex.

MOLECULAR STRUCTURE

[0046] FIG. 1 schematically illustrates an example copolymer molecule of the present disclosure, in an embodiment. A block copolymer molecule of the present disclosure includes in each repeat unit more than 60, or more than 100, or more than 150, or more than 200, or more than 250, or more than 300, or more than 350, or more than 400, or more than 450, or more than 500, or more than 600, or more than 700, or more than 800, or more than 900, or more than 1000 amino acid residues, or from 60 to 1000, or from 100 to 1000, or from 200 to 1000, or from 300 to 1000, or from 400 to 1000, or from 500 to 1000, or from 150 to 1000, or from 150 to 400, or from 150 to 500, or from 150 to 750, or from 200 to 400, or from 200 to 500, or from 200 to 750, or from 250 to 350, or from 250 to 400, or from 250 to 500, or from 250 to 750, or from 250 to 1000, or from 300 to 500, or from 300 to 750 amino acid residues. Each repeat unit of the polypeptide molecules of this disclosure can have a molecular weight from 20 kDal to 100 kDal, or greater than 20 kDal, or greater than 10 kDal, or greater than 5 kDal, or from 5 to 60 kDal, or from 5 to 40 kDal, or from 5 to 20 kDal, or from 5 to 100 kDal, or from 5 to 50 kDal, or from 10 to 20 kDal, or from 10 to 40 kDal, or from 10 to 60 kDal, or from 10 to 100 kDal, or from 10 to 50 kDal, or from 20 to 100 kDal, or from 20 to 80 kDal, or from 20 to 60 kDal, or from 20 to 40 kDal, or from 20 to 30 kDal. A copolymer molecule of the present disclosure can include in each repeat unit more than 300 amino acid residues. A copolymer molecule of the present disclosure can include in each repeat unit about 315 amino acid residues. These amino acid residues are organized within the molecule at several different levels. A copolymer molecule of the present disclosure includes from 2 to 20 occurrences of a repeat unit. After concatenating the repeat unit, the polypeptide molecules of this disclosure can be from 20 kDal to 2000 kDal, or greater than 20 kDal, or greater than 10 kDal, or greater than 5 kDal, or from 5 to 400 kDal, or from 5 to 300 kDal, or from 5 to 200 kDal, or from 5 to 100 kDal, or from 5 to 50 kDal, or from 5 to 500 kDal, or from 5 to 1000 kDal, or from 5 to 2000 kDal, or from 10 to 400 kDal, or from 10 to 300 kDal, or from 10 to 200 kDal, or from 10 to 100 kDal, or from 10 to 50 kDal, or from 10 to 500 kDal, or from 10 to 1000 kDal, or from 10 to 2000 kDal, or from 20 to 400 kDal, or from 20 to 300 kDal, or from 20 to 200 kDal, or from 40 to 300 kDal, or from 40 to 500 kDal, or from 20 to 100 kDal, or from 20 to 50 kDal, or from 20 to 500 kDal, or from 20 to 1000 kDal, or from 20 to 2000 kDal. As shown in FIG. 1, each "repeat unit" of a copolymer fiber comprises from two to twenty "quasi-repeat" units (i.e., n3 is from 2 to 20). Quasi-repeats do not have to be exact repeats. Each repeat can be made up of concatenated quasi-repeats. Equation 1 shows the composition of a quasi-repeat unit according the present disclosure.

(GGY-CGPG-X m-GPS-CA)^. (Equation 1) [0047] The variable compositional element Xi (termed a "motif) is according to any one of the following amino acid sequences shown in Equation 2 and X 1 varies randomly within each quasi-repeat unit.

Xi = SGGQQ or GAGQQ or GQGPY or AGQQ or SQ (Equation 2)

[0048] Referring again to Equation 1, the compositional element of a quasi -repeat unit represented by "GGY-[GPG-Xi] n i-GPS" in Equation 1 is referred to a "first region." A quasi-repeat unit is formed, in part by repeating from 4 to 8 times the first region within the quasi-repeat unit. That is, the value of ni indicates the number of first region units that are repeated within a single quasi-repeat unit, the value of ni being any one of 4, 5, 6, 7 or 8. The compositional element represented by "(A)^" is referred to a "second region" and is formed by repeating within each quasi-repeat unit the amino acid sequence "A" n 2 times. That is, the value of n 2 indicates the number of second region units that are repeated within a single quasi-repeat unit, the value of n 2 being any one of 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20. In some embodiments, the repeat unit of a polypeptide of this disclosure has at least 95% sequence identity to a sequence containing quasi-repeats described by Equations 1 and 2. In some embodiments, the repeat unit of a polypeptide of this disclosure has at least 80%, or at least 90%, or at least 95%, or at least 99% sequence identity to a sequence containing quasi-repeats described by Equations 1 and 2.

[0049] The first region described in Equation 1 is considered a glycine-rich region. A region can be glycine-rich if 6 or more consecutive amino acids within a sequence are more than 45% glycine. A region can be glycine-rich if 12 or more consecutive amino acids within a sequence are more than 45% glycine. A region can be glycine-rich if 18 or more consecutive amino acids within a sequence are more than 45% glycine. A region can be glycine-rich if 4 or more, or 6 or more, or 10 or more, or 12 or more, or 15 or more, or 20 or more, or 25 or more, or 30 or more, or 40 or more, or 50 or more, or 60 or more, or 70 or more, or 80 or more, or 100 or more, or 150 or more consecutive amino acids within a sequence are more than 30%, or more than 40%, or more than 45%, or more than 50%, or more than 55% glycine, or more than 60% glycine, or more than 70% glycine, or more than 80% glycine, or from 30% to 80%, or from 40% to 80%, or from 45% to 80%, or from 30% to 55%, or from 30% to 50%, or from 30% to 45%, or from 30% to 40%, or from 40% to 50%, or 40% to 55%, or 40% to 60% glycine. A region can be glycine-rich if from 5 to 150, or from 10 to 150, or from 12 to 150, or from 12 to 100, or from 12 to 80, or from 12 to 60, or from 20 to 60 consecutive amino acids within a sequence are more than 30%, or more than 40%, or more than 45%, or more than 50%, or more than 55% glycine, or more than 60% glycine, or more than 70% glycine, or more than 80% glycine, or from 30% to 80%, or from 40% to 80%, or from 45% to 80%, or from 30% to 55%, or from 30% to 50%, or from 30% to 45%, or from 30% to 40%, or from 40% to 50%, or 40% to 55%, or 40% to 60% glycine. In addition, a glycine-rich region can have less than 10%, or less than 20%, or less than 30%, or less than 40% alanine, or from about 0% to 10%, or from about 0% to 20%, or from about 0% to 30%, or from about 0% to 40%, or alanine. A region can be alanine-rich if 4 or more, or 6 or more, or 8 or more, or 10 or more consecutive amino acids within a sequence are more than 70%, or more than 75%, or more than 80%, or more than 85%, or more than 90% alanine, or from 70% to about 100%, or from 75% to about 100%, or from 80% to about 100%, or from 85% to about 100%, or from 90% to about 100% alanine. A region can be alanine-rich if from 4 to 10, or from 4 to 12, or from 4 to 15, or from 6 to 10, or from 6 to 12, or from 6 to 15, or from 4 to 20, or from 6 to 20 consecutive amino acids within a sequence are more than 70%, or more than 75%, or more than 80%, or more than 85%, or more than 90% alanine, or from 70% to about 100%, or from 75% to about 100%, or from 80% to about 100%, or from 85% to about 100%), or from 90% to about 100% alanine. The repeats described in this disclosure can have 6, or more than 2, or more than 4 or more than 6, or more than 8, or more than 10, or more than 15, or more than 20, or from 2 to 25, or from 2 to 10, or from 4 to 10, or from 2 to 8, or from 4 to 8 alanine-rich regions. The repeats described in this disclosure can have 6, or more than 2, or more than 4 or more than 6, or more than 8, or more than 10, or more than 15, or more than 20, or from 2 to 25, or from 2 to 10, or from 4 to 10, or from 2 to 8, or from 4 to 8 glycine-rich regions.

[0050] As further described below, one example of a copolymer molecule includes three "long" quasi-repeats followed by three "short" quasi-repeat units. A "long" quasi-repeat unit is comprised of quasi-repeat units that do not use the same X 1 constituent (as shown in Equation 2) more than twice in a row, or more than two times in a repeat unit. Each "short" quasi-repeat unit includes any of the amino acid sequences identified in Equation 2, but regardless of the amino acid sequences used, the same sequences are in the same location within the molecule. Furthermore, in this example copolymer molecule, no more than 3 quasi-repeats out of 6 share the same Xi . "Short" quasi-repeat units are those in which nl=4 or 5 (as shown in Equation 1). Long quasi-repeat units are defined as those in which nl=6, 7 or 8 (as shown in Equation 1).

[0051] In some embodiments, the repeat unit of the copolymer is composed of X qr quasi- repeat units, where X qr is a number from 2 to 20, and the number of short quasi-repeat units is X sqr and the number of long quasi-repeat units is X lqr , where

(Equation 3) and X sqr is a number from 1 to (X qr -1) and Xi qr is a number from 1 to (X qr -1).

[0052] In another embodiment, nl is from 4 to 5 for at least half of the quasi-repeat units. In yet another embodiment, n2 is from 5 to 8 for at least half of the quasi-repeat units.

[0053] One feature of copolymer molecules of the present disclosure is the formation of nano-crystalline regions that, while not wishing to be bound by theory, are believed to form from the stacking of beta-sheet regions, and amorphous regions composed of alpha-helix structures, beta-turn structures, or both. Poly-alanine regions (or in some species (GA) n regions) in a molecule form crystalline beta-sheets within major ampullate (MA) fibers.

Other regions within a repeat unit of major ampullate and flagelliform spider silks (for example containing GPGGX, GPGQQ, GGX where X = A, S or Y, GPG, SGGQQ, GAGQQ, GQGPY, AGQQ, and SQ, may form amorphous rubber-like structures that include alpha- helices and beta-turn containing structures. Furthermore, secondary, tertiary and quaternary structure is imparted to the morphology of the fibers via amino acid sequence and length, as well as the conditions by which the fibers are formed, processed and post-processed.

Materials characterization techniques (such as MR, FTIR and x-ray diffraction) have suggested that the poly-alanine crystalline domains within natural MA spider silks and recombinant silk derived from MA spider silk sequences are typically very small (<10 nm). Fibers can be highly crystalline or highly amorphous, or a blend of both crystalline and amorphous regions, but fibers with optimal mechanical properties have been speculated to be composed of 10-40% crystalline material by volume. In some embodiments, the repeat unit of a polypeptide described in this disclosure has at least 80%>, or at least 90%, or at least 95%, or at least 99% sequence identity to a MA dragline silk protein sequence. In some

embodiments, the repeat unit of a polypeptide described in this disclosure has at least 80%, or at least 90%, or at least 95%, or at least 99% sequence identity to a MaSp2 dragline silk protein sequence. In some embodiments, the repeat unit of a polypeptide described in this disclosure has at least 80%, or at least 90%, or at least 95%, or at least 99% sequence identity to a spider dragline silk protein sequence. In some embodiments, a quasi repeat unit of a polypeptide described in this disclosure has at least 80%, or at least 90%, or at least 95%, or at least 99% sequence identity to a MA dragline silk protein sequence. In some

embodiments, a quasi repeat unit of a polypeptide described in this disclosure has at least 80%), or at least 90%, or at least 95%, or at least 99% sequence identity to a MaSp2 dragline silk protein sequence. In some embodiments, a quasi repeat unit of a polypeptide described in this disclosure has at least 80%, or at least 90%, or at least 95%, or at least 99% sequence identity to a spider dragline silk protein sequence. [0054] The repeat unit of the proteinaceous block copolymer that forms fibers with good mechanical properties can be synthesized using a portion of a silk polypeptide. Some exemplary sequences that can be used as repeats in the proteinaceous block copolymers of this disclosure are shown in Table 1. These polypeptide repeat units contain alanine-rich regions and glycine-rich regions, and are 150 amino acids in length or longer. These exemplary sequences were demonstrated to express using a Pichia expression system as taught in co-owned PCT Publication WO 2015042164.

Table 1 : Exemplary sequences that can be used as repeat units

Seq. ID No. AA

6 GPGARRQGPGSQGPGSGGQQGPGGQGPYGSGQQGPGGAGQQGPGGQGPYGPGAAAAAA

AAAGGYGPGAGQQGPGGAGQQGPGSQGPGGQGPYGPGAGQQGPGSQGPGSGGQQGPG

GQGPYGPSAAAAAAAAGGYGPGAGQQGPGSQGPGSGGQQGPGGQGPYGPGAAAAAAA VG

GYGPGAGQQGPGSQGPGSGGQQGPGGQGPYGPSAAAAAAAAGGYGPGAGQQGPGSQG P

GSGGQQGPGGQGPYGPSAAAAAAAA

7 GGYGPGAGQQGPGSGGQQGPGGQGPYGSGQQGPGGAGQQGPGGQGPYGPGAAAAAAAA

AGGYGPGAGQQGPGGAGQQGPEGPGSQGPGSGGQQGPGGQGPYGPGAAAAAAAVGGY G

PGAGQQGPGSQGPGSGGQQGPGGQGPYGPSAAAAAAAAGGYGPGAGQQGPGSQGPGS G

GQQGPGGQGPYGPSAAAAAAAAGGYGPGAGQQGPGSGGQQGPGGQGPYGSGQQGPGG A

GQQGPGGQGPYGPGAAAAAAAAA

8 GVFSAGQGATPWENSQLAESFISRFLRFIGQSGAFSPNQLDDMSSIGDTLKTAI EKMAQSRKSSK

SKLQALNMAFASSMAEIAVAEQGGLSLEAKTNAIASALSAAFLETTGYVNQQFVNEI KTLIFMIA

QASSNEISGSAAAAGGSSGGGGGSGQGGYGQGAYASASAAAAYGSAPQGTGGPASQG PSQQ

GPVSQPSYGPSATVAVTAVGGRPQGPSAPRQQGPSQQGPGQQGPGGRGPYGPSAAAA AAA

A

9 GAGAGAGAGAGAGAGAGSGASTSVSTSSSSGSGAGAGAGSGAGSGAGAGSGAGAGAGAGG AG AG FG SG LG LG YG VG LSS AQAQAQAQAAAQAQAQAQAQAYAAAQAQAQAQAQAQAAA AAAAAAAAGAGAGAGAGAGAGAGAGSGASTSVSTSSSSGSGAGAGAGSGAGSGAGAGSGA GAG AG AGG AG AG FGSG LG LG YG VG LSSAQAQAQAQAAAQAQAQAQAQAYAAAQAQAQA QAQAQAAAAAAAAAAA

10 GAGAGAGAGAGAGAGAGSGASTSVSTSSSSGSGAGAGAGSGAGSGAGAGSGAGAGAGAGG

AG AAFGSG LG LG YG VG LSSAQAQAQAQAAAQAQAD AQAQAYAAAQAQAQAQAQAQAAAA AAAAAAAGAGAGAGAGSGAGAGAGSGASTSVSTSSSSGSGAGAGAGSGAGSGAGAGSGAG A GAGAGGAGAGFGSGLGLGYGVGLSSAQAQAQAQAAAQAQADAQAQAYAAAQAQAQAQA QAQAAAAAAAAAAA

11 GAGAGAGAGSGAGAGAGSGASTSVSTSSSSGSGAGAGAGSGAGSGAGAGSGAGAGAGAGG

AGAGFGSGLGLGYGVGLSSAQAQAQSAAAARAQADAQAQAYAAAQAQAQAQAQAQAAAA

AAAAAAAGAGAGAGAGAGAGAGAGSGASTSVSTSSSSASGAGAGAGSGAGSGAGAGS GAGA

GAGAGGAGAGFGSGLGLGYGVGLSSAQAQAQAQAAAQAQAQAQAQALAAAQAQAQAQ A

QAQAAAATAAAAAA

12 GGYGPGAGQQGPGGAGQQGPGSQGPGGQGPYGPGAGQQGPGSQGPGSGGQQGPGGQG

PYGPSAAAAAAAAGGYGPGAGQQGPGSQGPGSGGQQGPGSQGPGSGGQQGPGGQGPYGP SAAAAAAAAAGG YG PG AGQQG PGSQG PGSGGQQG PGGQG PYG PG AAAAAAAVGG YG PGA GQQGPGSQGPGSGGQQGPGGQGPYGPSAAAAAAAAGGYGPGAGQQGPGSQGPGSGGQQ G PGGQG PYG PSAAAAAAAA

13 GGYGPGAGQQGPGGAGQQGPGSQGPGGQGPYGPGAGQQGPGSQGPGSGGQQGPGGQG

PYGPSAAAAAAAAGGYGPGAGQQGPGSQGPGSGGQQGPGSQGPGSGGQQGPGGQGPYGP SAAAAAAAAGG YG PG AGQQG PGSQG PGSGGQQG PGGQG PYG PG AAAAAAAVGG YG PG AG QQGPGSQGPGSGGQQGPGGQGPYGPSAAAAAAAAGGYGPGAGQQGPGSQGPGSGGQQG PG GQG PYG PSAAAAAAAA Seq. ID No. AA

14 GHQGPHRKTPWETPEMAENFMN NVREN LEASRI FPDELMKDMEAITNTMIAAVDGLEAQHR

SSYASLQAMNTAFASSMAQLFATEQDYVDTEVIAGAIGKAYQQITGYENPHLASEVTRLI QLFRE EDDLEN EVEISFADTDNAIARAAAGAAAGSAAASSSADASATAEGASGDSGFLFSTGTFGRGGA G AG AG AAAASAAAASAAAAG AEG D RG LFFSTG D FG RGG AG AG AG AAAASAAAASAAAA

15 GGAQKHPSGEYSVATASAAATSVTSGGAPVGKPGVPAPIFYPQGPLQQGPAPGPSNVQPG TS

QQGPIGGVGESNTFSSSFASALGGNRGFSGVISSASATAVASAFQKGLAPYGTAFALSAA SAAAD AYNSIGSGASASAYAQAFARVLYPLLQQYGLSSSADASAFASAIASSFSTGVAGQGPSVP YVGQQ QPSIMVSAASASAAASAAAVGGGPVVQGPYDGGQPQQPNIAASAAAAATATSS

16 GGQGGRGGFGGLGSQGEGGAGQGGAGAAAAAAAAGADGGFGLGGYGAGRGYGAGLGGA

GGAGAASAAAAAGGQGGRSGFGGLGSQGAGGAGQGGAGAAAAAAAAGADGGSGLGGYGA

GRGYGASLGGADGAGAASAAAAAGGQGGRGGFGGLGSQGAGGAGQGGAGAAAAAAAA SG

DGGSGLGGYGAGRGYGAGLGGAGGAGAASAAAAAGGEGGRGGFGGLGSQGAGGAGQG GS

LAAAAAAAA

17 GPGGYGGPGQPGPGQGQYGPGPGQQGPRQGGQQGPASAAAAAAAGPGGYGGPGQQGPR

QGQQQGPASAAAAAAAAAAGPRGYGGPGQQGPVQGGQQGPASAAAAAAAAGVGGYGGP GQQGPGQGQYGPGTGQQGQGPSGQQGPAGAAAAAAGGAAGPGGYGGPGQQGPGQGQY GPGTGQQGQGPSGQQGPAGAAAAAAAAAGPGGYGGPGQQGPGQGQYGPGAGQQGQGP GSQQGPASAAAAAA

18 GSGAGQGTGAGAGAAAAAAGAAGSGAGQGAGSGAGAAAAAAAASAAGAGQGAGSGSGAG

AAAAAAAAAGAGQGAGSGSGAGAAAAAAAAAAAAQQQQQQQAAAAAAAAAAAAAGSGQ

GASFGVTQQFGAPSGAASSAAAAAAAAAAAAAGSGAGQEAGTGAGAAAAAAAAGAAG SGA

GQGAGSGAGAAAAAAAAASAAGAGQGAGSGSGAGAAAAAAAAAAAAQQQQQQQAAAA A

AAAAAAAA

19 GGAQKQPSGESSVATASAAATSVTSAGAPVGKPGVPAPI FYPQGPLQQGPAPGPSYVQPATSQ

QGPIGGAGRSNAFSSSFASALSGN RGFSEVISSASATAVASAFQKGLAPYGTAFALSAASAAADA YNSIGSGANAFAYAQAFARVLYPLVQQYGLSSSAKASAFASAIASSFSSGAAGQGQSIPY GGQQ QP P MTI S AAS AS AG AS AAAV KGGQVGQG PYGG QQQSTAAS AS AAATTATA

20 GADGGSGLGGYGAGRGYGAGLGGADGAGAASAAAAAGGQGGRGGFGRLGSQGAGGAGQG

GAGAAAAVAAAGGDGGSGLGGYGAGRGYGAGLGGAGGAGAASAAAAAGGQGGRGGFGGL GSQGAGGAGQGGAGAAASGDGGSGLGGYGAGRGYGAGLGGADGAGAASAASAAGGQGGR GGFGGLGSQGAGGAGQGGAGAAAAAATAGGDGGSGLGGYGAGRGYGAGLGGAGGAGAAS AAAAA

21 GAGAGQGGRGGYGQGGFGGQGSGAGAGASAAAGAGAGQGGRGGYGQGGFGGQGSGAG

AGASAAAGAGAGQGGRGGYGQGGFGGQGSGAGAGASAAAAAGAGQGGRGGYGQGGLGG

SGSGAGAGAGAAAAAAAGAGGYGQGGLGGYGQGAGAGQGGLGGYGSGAGAGASAAAA AG

AGGAGQGGLGGYGQGAGAGQGGLGGYGSGAGAGAAAAAAAGAGGSGQGGLGGYGSGG G

AGGASAAAA

22 GAYAYAYAIANAFASI LANTGLLSVSSAASVASSVASAIATSVSSSSAAAAASASAAAAASAGASA

ASSASASSSASAAAGAGAGAGAGASGASGAAGGSGGFGLSSGFGAGIGGLGGYPSGALGG LGI PSGLLSSGLLSPAANQRIASLIPLI LSAISPNGVNFGVIGSN IASLASQISQSGGGIAASQAFTQALLE LVAAFIQVLSSAQIGAVSSSSASAGATANAFAQSLSSAFAG Seq. ID No. AA

23 GAAQKQPSGESSVATASAAATSVTSGGAPVGKPGVPAPI FYPQGPLQQGPAPGPSNVQPGTSQ

QGPIGGVGGSNAFSSSFASALSLNRGFTEVISSASATAVASAFQKGLAPYGTAFALSAAS AAADA YNSIGSGANAFAYAQAFARVLYPLVRQYGLSSSGKASAFASAIASSFSSGTSGQGPSIGQ QQPPV TISAASASAG AS A A AVG GGQVGQGPYGG QQQST A AS AS A A A ATATS

24 GAAQKQPSGESSVATASAAATSVTSGGAPVGKPGVPAPI FYPQGPLQQGPAPGPSNVQPGTSQ

QGPIGGVGGSNAFSSSFASALSLNRGFTEVISSASATAVASAFQKGLAPYGTAFALSAAS AAADA YNSIGSGANAFAYAQAFARVLYPLVRQYGLSSSGKASAFASAIASSFSSGTSGQGPSIGQ QQPPV TISAASASAG AS A A AVG GGQVGQGPYGG QQQST A AS AS A A A ATATS

25 GAAQKQPSGESSVATASAAATSVTSGGAPVGKPGVPAPI FYPQGPLQQGPAPGPSNVQPGTSQ

QGPIGGVGGSNAFSSSFASALSLNRGFTEVISSASATAVASAFQKGLAPYGTAFALSAAS AAADA YNSIGSGANAFAYAQAFARVLYPLVQQYGLSSSAKASAFASAIASSFSSGTSGQGPSIGQ QQPPV TISAASASAG AS A A AVG GGQVGQGPYGG QQQST A AS AS A A A ATATS

26 GGAQKQPSGESSVATASAAATSVTSAGAPVGKPGVPAPI FYPQGPLQQGPAPGPSNVQPGTSQ

QGPIGGVGGSNAFSSSFASALSLNRGFTEVISSASATAVASAFQKGLAPYGTAFALSAAS AAADA YNSIGSGANAFAYAQAFARVLYPLVQQYGLSSSAKASAFASAIASSFSSGTSGQGPSNGQ QQPP VTISAASASAGASAAAVGGGQVSQGPYGGQQQSTAASASAAAATATS

27 GGAQKQPSGESSVATASAAATSVTSAGAPGGKPGVPAPI FYPQGPLQQGPAPGPSNVQPGTS

QQGPIGGVGGSNAFSSSFASALSLN RGFTEVISSASATAVASAFQKGLAPYGTAFALSAASAAAD AYNSIGSGANAFAYAQAFARVLYPLVQQYGLSSSAKASAFASAIASSFSSGTSGQGPSIG QQQPP VTISAASASAGASAAAVGGGQVGQGPYGGQQQSTAASASAAAATATS

28 GPGGYGGPGQQGPGQGQQQGPASAAAAAAAAGPGGYGGPGQQGPGQGQQQGPASAAA

AAAAAAG PG G YGG PGQQR PG QAQYG RGTGQQG QG PGAQQG P AS AAAAAAAG AG LYG G P GQQG PGQGQQQG PASAAAAAAAAAAAG PGGYGG PGQQG PGQAQQQG PASAAAAAAAG P GGYSGPGQQGPGQAQQQGPASAAAAAAAAAGPGGYGGPGQQGPGQGQQQGPASAAAAA AATAA

29 GAGGDGGLFLSSGDFGRGGAGAGAGAAAASAAAASSAAAGARGGSGFGVGTGGFGRGGAG

DGASAAAASAAAASAAAAGAGGDSGLFLSSGDFGRGGAGAGAGAAAASAAAASAAAAGTG G VGGLFLSSGDFGRGGAGAGAGAAAASAAAASSAAAGARGGSGFGVGTGGFGRGGPGAGTG A AAASAAAASAAAAGAGGDSGLFLSSEDFGRGGAGAGTGAAAASAAAASAAAA

30 GAGRGYGGGYGGGAAAGAGAGAGAGRGYGGGYGGGAGSGAGSGAGAGGGSGYGRGAGA

GAGAGAAAAAGAGAGGAGGYGGGAGAGAGASAAAGAGAGAGGAGGYGGGYGGGAGAGA

GAGAAAAAGAGAGAGAGRGYGGGFGGGAGSGAGAGAGAGGGSGYGRGAGGYGGGYGG G

AGTGAGAAAATGAGAGAGAGRGYGGGYGGGAGAGAGAGAGAGGGSGYGRGAGAGASV A

A

31 GALGQGASVWSSPQMAEN FMNGFSMALSQAGAFSGQEMKDFDDVRDIMNSAMDKMIRSG

KSGRGAMRAMNAAFGSAIAEIVAANGGKEYQIGAVLDAVTNTLLQLTGNADNGFLNEISR LITL FSSVEAN DVSASAGADASGSSGPVGGYSSGAGAAVGQGTAQAVGYGGGAQGVASSAAAGAT NYAQGVSTGSTQNVATSTV 1 1 1 1 NVAGSTATGYNTGYGIGAAAGAAA Seq. ID No. AA

32 GGQGGQGGYDGLGSQGAGQGGYGQGGAAAAAAAASGAGSAQRGGLGAGGAGQGYGAGS

GGQGGAGQGGAAAATAAAAGGQGGQGGYGGLGSQGSGQGGYGQGGAAAAAAAASGDG

GAGQEGLGAGGAGQGYGAGLGGQGGAGQGGAAAAAAAAAGGQGGQGGYGGLGSQGAG

QGGYGQGGAAAAAAAASGAGGAGQGGLGAAGAGQGYGAGSGGQGGAGQGGAAAAAAA A

A

33 GGQGGQGGYGGLGSQGAGQGGYGQGGVAAAAAAASGAGGAGRGGLGAGGAGQEYGAVS

GGQGGAGQGGEAAAAAAAAGGQGGQGGYGGLGSQGAGQGGYGQGGAAAAAAAASGAG GARRGGLGAGGAGQGYGAGLGGQGGAGQGSASAAAAAAAGGQGGQGGYGGLGSQGSGQ GGYGQGGAAAAAAAASGAGGAGRGSLGAGGAGQGYGAGLGGQGGAGQGGAAAAASAAA

34 GPGGYGGPGQQGPGQGQYGPGTGQQGQGPGGQQGPVGAAAAAAAAVSSGGYGSQGAGQ

GGQQGSGQRGPAAAGPGGYSGPGQQGPGQGGQQGPASAAAAAAAAAGPGGYGGSGQQG PGQGRGTGQQGQGPGGQQGPASAAAAAAAGPGGYGGPGQQGPGQGQYGPGTGQQGQG PASAAAAAAAGPGGYGGPGQQGPGQGQYGPGTGQQGQGPGGQQGPGGASAAAAAAA

35 GGYGPGAGQQGPGSGGQQGPGGQGPYGSGQQGPGGAGQQGPGGQGPYGPGAAAAAAAA

AGGYGPGAGQQGPGGAGQQGPGSQGPGGQGPYGPGAGQQGPGSQGPGSGGQQGPGGQ GPYGPSAAAAAAAAAGGYGPGAGQRSQGPGGQGPYGPGAGQQGPGSQGPGSGGQQGPGG QG PYG PS AAAAAAAAG PG AG RQG PGSQG PGSGGQQG PG GQG PYG PSAAAAAAAA

36 GQGGQGGQGGLGQGGYGQGAGSSAAAAAAAAAAAAAAGRGQGGYGQGSGGNAAAAAAA

AAAAASGQGSQGGQGGQGQGGYGQGAGSSAAAAAAAAAAAAASGRGQGGYGQGAGGNA AAA A A A A A A A A A AG QG G QG G YG G LG QG G YG QG AG SS A A A A A A A A A A A AG G QG G QG QG G YG QG SG G S A A A A A A A A A A A A A A AG RGQGGYGQGSGGN A A A A A A A A A A A A A A

37 G RG PGG YG PGQQG PGG PG AAAAAAG PGG YG PGG YG PGQQG PGG PG AAAAAAAG RG PGG

YGPGQQGPGQQGPGGSGAAAAAAGRGPGGYGPGQQGPGGPGAAAAAAGPGGYGPGQQG PGAAAAAAAAGRGPGGYGPGQQGPGGPGAAAAAAAGRGPGGYGPGQQGPGQQGPGGSG AAAAAAG RG PG G YG PG QQG PGG PG AAAAAAG PG G YG PG QQG PGAAAAAAAA

38 GRGPGGYGPGQQGPGGSGAAAAAAGRGPGGYGPGQQGPGGPGAAAAAAGPGGYGPGQQ

GTG A A A A A A AG SG AG G YG PGQQG PGG PG AAAAAAG PGG YG PGQQG PG AAAAAAAG SG PG GYG PGQQG PGGSSAAAAAAG PG RYG PGQQG PG AAAAASAG RG PGG YG PGQQG PGG PG AA AAAAGPGGYGPGQQGPGAAAAAAAGSGPGGYGPGQQGPGGPGAAAAAAA

39 GAAATAGAGASVAGGYGGGAGAAAGAGAGGYGGGYGAVAGSGAGAAAAASSGAGGAAGY

GRGYGAGSGAGAGAGTVAAYGGAGGVATSSSSATASGSRIVTSGGYGYGTSAAAGAGVAA GS YAGAVNRLSSAEAASRVSSN IAAIASGGASALPSVISNIYSGVVASGVSSNEALIQALLELLSALVH VLSSASIGNVSSVGVDSTLNVVQDSVGQYVG

40 GGQGGFSGQGQGGFGPGAGSSAAAAAAAAAAARQGGQGQGGFGQGAGGNAAAAAAAAA

AAAAAQQGGQGGFSGRGQGGFGPGAGSSAAAAAAGQGGQGQGGFGQGAGGNAAAAAAA AAAAAAAAGQGGQGRGGFGQGAGGNAAAAAAAAAAAAAAAQQGGQGGFGGRGQGGFG PG AG SS A A A A A AG QGGQGRGGFGQGAGGN A A A AS A A A A AS A A A AG Q

41 GGYGPGAGQQGPGGAGQQGPGSQGPGGAGQQGPGGQGPYGPGAAAAAAAVGGYGPGAG

QQGPGSQGPGSGGQQGPGGQGPYGPSAAAAAAAAGGYGPGAGQQGPGSQGPGSGGQQG PG G LG PYG PS AAAAAAAAGG YG PG AG QQG PG SQG PGSGGQQRPGG LG PYG PSAAAAAAAA GG YG PG AG QQG PG SQG PGSGGQQRPGG LG PYG PSAAAAAAAA Seq. ID No. AA

42 GAGAGGGYGGGYSAGGGAGAGSGAAAGAGAGRGGAGGYSAGAGTGAGAAAGAGTAGGYS

GGYGAGASSSAGSSFISSSSMSSSQATGYSSSSGYGGGAASAAAGAGAAAGGYGGGYGAG AG AGAAAASGATGRVANSLGAMASGGINALPGVFSNI FSQVSAASGGASGGAVLVQALTEVIALLL HI LSSASIGNVSSQGLEGSMAIAQQAIGAYAG

43 GAGAGGAGGYAQGYGAGAGAGAGAGTGAGGAGGYGQGYGAGSGAGAGGAGGYGAGAGA

GAGAGDASGYGQGYGDGAGAGAGAAAAAGAAAGARGAGGYGGGAGAGAGAGAGAAGGY GQGYGAGAGEGAGAGAGAGAVAGAGAAAAAGAGAGAGGAEGYGAGAGAGGAGGYGQSY GDGAAAAAGSGAGAGGSGGYGAGAGAGSGAGAAGGYGGGAGA

44 GPGGYGPGQQGPGGYGPGQQGPGRYGPGQQGPSGPGSAAAAAAGSGQQGPGGYGPRQQ

GPGGYGQGQQGPSGPGSAAAASAAASAESGQQGPGGYGPGQQGPGGYGPGQQGPGGYGP GQQG PSG PGSAAAAAAAASG PGQQG PGGYG PGQQG PGGYG PGQQG PSG PGSAAAAAAAA SGPGQQGPGGYGPGQQGPGGYGPGQQGLSGPGSAAAAAAA

45 GRGPGGYGQGQQGPGGPGAAAAAAGPGGYGPGQQGPGAAAAAAAGSGPGGYGPGQQGP

G RSG AAAAAAAAG RG PG G YG PGQQG PG G PG AAAAAAG PG G YG PGQQG PG AAAAAS AG RG PGGYGPGQQGPGGSGAAAAAAGRGPGGYGPGQQGPGGPGAAAAAAAGRGPGGYGPGQQ G PGQQG PGGSG AAAAAAG RG PGGYG PGQQG PGG PG AAAAAA

46 GVGAGGEGGYDQGYGAGAGAGSGGGAGGAGGYGGGAGAGSGGGAGGAGGYGGGAGAG

AGAGAGGAGGYGGGAGAGTGARAGAGGVGGYGQSYGAGASAAAGAGVGAGGAGAGGAG GYGQGYGAGAGIGAGDAGGYGGGAGAGASAGAGGYGGGAGAGAGGVGGYGKGYGAGSGA GAAAAAGAGAGSAGGYGRGDGAGAGGASGYGQGYGAGAAA

47 GYGAGAGRGYGAGAGAGAGAVAASGAGAGAGYGAGAGAGAGAGYGAGAGRGYGAGAGA

GAGSGAASGAGAGAGYGAGAGAGAGYGAGAGSGYGTGAGAGAGAAAAGGAGAGAGYGA GAGRGYGAGAGAGAASGAGAGAGAGAASGAGAGSGYGAGAAAAGGAGAGAGGGYGAGA GRGYGAGAGAGAGAGSGSGSAAGYGQGYGSGSGAGAAA

48 GQGTDSSASSVSTSTSVSSSATGPDTGYPVGYYGAGQAEAAASAAAAAAASAAEAATIAG LGYG

RQGQGTDSSASSVSTSTSVSSSATGPDMGYPVGNYGAGQAEAAASAAAAAAASAAEAATI ASL GYGRQGQGTDSSASSVSTSTSVSSSATGPGSRYPVRDYGADQAEAAASAAAAAAAAASAA EEIA SLGYGRQ

49 GQGTDSVASSASSSASASSSATGPDTGYPVGYYGAGQAEAAASAAAAAAASAAEAATIAG LGY

GRQGQGTDSSASSVSTSTSVSSSATGPGSRYPVRDYGADQAEAAASATAAAAAAASAAEE IASL GYGRQGQGTDSVASSASSSASASSSATGPDTGYPVGYYGAGQAEAAASAAAAAAASAAEA ATI AGLGYGRQ

50 G QG G QG G YG G LG QG G YG QG AG SS A A A A A A A A A A A A AG G QG G QG QG R YG QG AG SS A A A A

AAAAAAAAAAGRGQGGYGQGSGGNAAAAAAAAAAAASGQGSQGGQGGQGQGGYGQGA GSSAAAAAAAAAAAAASGRGQGGYGQGAGGNAAAAAAAAAAAAAAGQGGQGGYGGLGQ GGYGQGAGSSAAAAAAAAAAAA

51 GGLGGQGGLGGLGSQGAGLGGYGQGGAGQGGAAAAAAAAGGLGGQGGRGGLGSQGAGQ

GGYGQGGAGQGGAAAAAAAAGGLGGQGGLGALGSQGAGQGGAGQGGYGQGGAAAAAA GGLGGQGGLGGLGSQGAGQGGYGQGGAGQGGAAAAAAAAGGLGGQGGLGGLGSQGAGP GGYGQGGAGQGGAAAAAAAA Seq. ID No. AA

63 GASGAGQGQGYG QQG QG G SS A A A A A A A A A A A A A A AQG QG QG YG QQG QG S A A A A A A A A A

AGASGAGQGQGYGQQGQGSAAAAAAAAAAGASGAGQGQGYGQQGQGGSSAAAAAAAAA AAAAAAAQGQGYGQQGQGSAAAAAAAAAGASGAGQGQGYGQQGQGGSSAAAAAAAAAA AAAAAA

64 GRGQGGYGQGSGGNAAAAAAAGQGGFGGQEGNGQGAGSAAAAAAAAAAAAGGSGQGRY

GGRGQGGYGQGAGAAASAAAAAAAAAAGQGGFGGQEGNGQGAGSAAAAAAAAAAAAGG SGQGGYGGRGQGGYGQGAGAAAAAAAAAAAAAAGQGGQGGFGSQGGNGQGAGSAAAAA AAAAA

65 GQNTPWSSTELADAFINAFMNEAGRTGAFTADQLDDMSTIGDTI KTAMDKMARSN KSSKGKL

QALNMAFASSMAEIAAVEQGGLSVDAKTNAIADSLNSAFYQTTGAANPQFVN EI RSLIN MFAQ SSAN EVSYGGGYGGQSAGAAASAAAAGGGGQGGYGNLGGQGAGAAAAAAASAA

66 GQNTPWSSTELADAFINAFLNEAGRTGAFTADQLDDMSTIGDTLKTAMDKMARSNKSSQS KL

QALNMAFASSMAEIAAVEQGGLSVAEKTNAIADSLNSAFYQTTGAVNVQFVNEIRSLISM FAQA

SAN EVSYGGGYGGGQGGQSAGAAAAAASAGAGQGGYGGLGGQGAGSAAAAAA

67 GGQGGQGGYGGLGSQGAGQGGYGQGGAAAAAASAGGQGGQGGYGGLGSQGAGQGGYG

GGAFSGQQGGAASVATASAAASRLSSPGAASRVSSAVTSLVSSGGPTNSAALSNTISNVV SQISS SN PGLSGCDVLVQALLEIVSALVHILGSANIGQVNSSGVGRSASIVGQSI NQAFS

68 GGAGQGGYGGLGGQGAGAAAAAAGGAGQGGYGGQGAGQGAAAAAASGAGQGGYEGPG

AGQGAGAAAAAAGGAGQGGYGGLGGQGAGQGAGAAAAAAGGAGQGGYGGLGGQGAGQ GAGAAAAAAGGAGQGGYGGQGAGQGAAAAAAGGAGQGGYGGLGSGQGGYGRQGAGAA AAAAAA

69 GASSAAAAAAATATSGGAPGGYGGYGPGIGGAFVPASTTGTGSGSGSGAGAAGSGGLGGL GS

SGGSGGLGGGNGGSGASAAASAAAASSSPGSGGYGPGQGVGSGSGSGAAGGSGTGSGAGG P

GSGGYGGPQFFASAYGGQGLLGTSGYGNGQGGASGTGSGGVGGSGSGAGSNS

70 GQPIWTNPNAAMTMTNN LVQCASRSGVLTADQMDDMGMMADSVNSQMQKMGPN PPQ

HRLRAMNTAMAAEVAEVVATSPPQSYSAVLNTIGACLRESMMQATGSVDNAFTNEVMQLV K MLSADSAN EVSTASASGASYATSTSSAVSSSQATGYSTAAGYGNAAGAGAGAAAAVS

71 GQKIWTNPDAAMAMTNN LVQCAGRSGALTADQMDDLGMVSDSVNSQVRKMGANAPPHKI

KAMSTAVAAGVAEVVASSPPQSYSAVLNTIGGCLRESMMQVTGSVDNTFTTEMMQMVNMF AADNANEVSASASGSGASYATGTSSAVSTSQATGYSTAGGYGTAAGAGAGAAAAA

72 GSGYGAGAGAGAGSGYGAGAGAGSGYGAGAGAGAGSGYVAGAGAGAGAGSGYGAGAGAG

AGSSYSAGAGAGAGSGYGAGSSASAGSAVSTQTVSSSATTSSQSAAAATGAAYGTRASTG SGA SAGAAASGAGAGYGGQAGYGQGGGAAAYRAGAGSQAAYGQGASGSSGAAAAA

73 GGQGGRGGFGGLSSQGAGGAGQGGSGAAAAAAAAGGDGGSGLGDYGAGRGYGAGLGGAG

GAGVASAAASAAASRLSSPSAASRVSSAVTSLISGGGPTNPAALSNTFSNVVYQISVSSP GLSGCD VLIQALLELVSALVHI LGSAI IGQVNSSAAGESASLVGQSVYQAFS

74 GVGQAATPWENSQLAEDFI NSFLRFIAQSGAFSPNQLDDMSSIGDTLKTAIEKMAQSRKSSKSKL

QALNMAFASSMAEIAVAEQGGLSLEAKTNAIANALASAFLETTGFVNQQFVSEI KSLIYMIAQAS

SN EISGSAAAAGGGSGGGGGSGQGGYGQGASASASAAAA Seq. ID No. AA

75 GGGDGYGQGGYGNQRGVGSYGQGAGAGAAATSAAGGAGSGRGGYGEQGGLGGYGQGAG

AGAASTAAGGGDGYGQGGYGNQGGRGSYGQGSGAGAGAAVAAAAGGAVSGQGGYDGEG GQGGYGQGSGAGAAVAAASGGTGAGQGGYGSQGSQAGYGQGAGFRAAAATAAA

76 GAGAGYGGQVGYGQGAGASAGAAAAGAGAGYGGQAGYGQGAGGSAGAAAAGAGAGRQA

GYGQGAGASARAAAAGAGTGYGQGAGASAGAAAAGAGAGSQVGYGQGAGASSGAAAAAG AGAGYGGQVGYEQGAGASAGAEAAASSAGAGYGGQAGYGQGAGASAGAAAA

77 GGAGQGGYGGLGGQGAGQGGLGGQRAGAAAAAAGGAGQGGYGGLGSQGAGRGGYGGVG

SGASAASAAASRLSSPEASSRVSSAVSN LVSSGPTNSAALSSTISNVVSQISASN PGLSGCDVLVQ

ALLEVVSALIQILGSSSIGQVNYGTAGQAAQIVGQSVYQALG

78 GGYGPGSGQQGPGGAGQQGPGGQGPYGPGSSSAAAVGGYGPSSGLQGPAGQGPYGPGAA

ASAAAAAGASRLSSPQASSRVSSAVSSLVSSGPTNSAALTNTISSVVSQISASN PGLSGCDVLIQAL LEI VSALVH 1 LGYSSIGQI NYDAAAQYASLVGQSVAQALA

79 GGAGAGQGSYGGQGGYGQGGAGAATATAAAAGGAGSGQGGYGGQGGLGGYGQGAGAGA

AAAAAAAAGGAGAGQGGYGGQGGQGGYGQGAGAGAAAAAAGGAGAGQGGYGGQGGYG QGGGAGAAAAAAAASGGSGSGQGGYGGQGGLGGYGQGAGAGAGAAASAAAA

80 GQGGQGGYGRQSQGAGSAAAAAAAAAAAAAAGSGQGGYGGQGQGGYGQSSASASAAASA

ASTVANSVSRLSSPSAVSRVSSAVSSLVSNGQVN MAALPNI ISN ISSSVSASAPGASGCEVIVQAL LEVITALVQIVSSSSVGYIN PSAVNQITNVVANAMAQVMG

81 GGAGQGGYGGLGGQGSGAAAAGTGQGGYGSLGGQGAGAAGAAAAAVGGAGQGGYGGVG

SAAASAAASRLSSPEASSRVSSAVSNLVSSGPTNSAALSNTISNVVSQISSSN PGLSGCDVLVQALL EVVSALIHI LGSSSIGQVNYGSAGQATQIVGQSVYQALG

82 GAGAGGAGGYGAGQGYGAGAGAGAAAGAGAGGARGYGARQGYGSGAGAGAGARAGGAG

GYGRGAGAGAAAASGAGAGGYGAGQGYGAGAGAVASAAAGAGSGAGGAGGYGRGAGAVA GAGAGGAGGYGAGAGAAAGVGAGGSGGYGGRQGGYSAGAGAGAAAAA

83 GQGGQGGYGGLGQGGYGQGAGSSAAAAAAAAAAAGRGQGGYGQGSGGNAAAAAAAAAA

AASG QG G QG G QG G QG QG G YG QG AG SS A A A A A A A A A A A A A A AG RGQGGYGQGAGGNAA AA A A A A A A A ASG QG G QG G QG G QG QG G YG QG AG SS A A A A A A A A A A A A A A

84 GGYGPGSGQQGPGQQGPGQQGPGQQGPYGAGASAAAAAAGGYGPGSGQQGPGVRVAAP

VASAAASRLSSSAASSRVSSAVSSLVSSGPTTPAALSNTISSAVSQISASNPGLSGCDVL VQALLEV VSALVH 1 LGSSSVGQI N YG ASAQYAQM VGQSVTQALV

85 GAGAGGAGYGRGAGAGAGAAAGAGAGAAAGAGAGAGGYGGQGGYGAGAGAGAAAAAGA

GAGGAAGYSRGGRAGAAGAGAGAAAGAGAGAGGYGGQGGYGAGAGAGAAAAAGAGSGG

AGGYGRGAGAGAAAGAGAAAGAGAGAGGYGGQGGYGAGAGAAAAA

86 GAGAGRGGYGRGAGAGGYGGQGGYGAGAGAGAAAAAGAGAGGYGDKEIACWSRCRYTVA

STTSRLSSAEASSRISSAASTLVSGGYLNTAALPSVISDLFAQVGASSPGVSDSEVLIQV LLEIVSSLI

H 1 LSSSS VG QV D FSS VG SS AAAVG QS M QVV M G

87 GAGAGAGGAGGYGRGAGAGAGAGAGAAAGQGYGSGAGAGAGASAGGAGSYGRGAGAGA

AAASGAGAGGYGAGQGYGAGAGAVASAAAGAGSGAGGAGGYGRGAVAGSGAGAGAGAGG

AGGYGAGAGAGAAAGAVAGGSGGYGGRQGGYSAGAGAGAAAAA

[0055] In an embodiment a block copolymer polypeptide repeat unit that forms fibers with good mechanical properties is synthesized using SEQ ID NO. 1. This repeat unit contains 6 quasi-repeats, each of which includes motifs that vary in composition, as described herein. This repeat unit can be concatenated 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1 , 12, 13, 14, 15, 16, 17, 18, 19 or 20 times to form polypeptide molecules from 20 kDal to 535 kDal, or greater than 20 kDal, or greater than 10 kDal, or greater than 5 kDal, or from 5 to 400 kDal, or from 5 to 300 kDal, or from 5 to 200 kDal, or from 5 to 100 kDal, or from 5 to 50 kDal, or from 5 to 600 kDal, or from 5 to 800 kDal, or from 5 to 1000 kDal, or from 10 to 400 kDal, or from 10 to 300 kDal, or from 10 to 200 kDal, or from 10 to 100 kDal, or from 10 to 50 kDal, or from 10 to 600 kDal, or from 10 to 800 kDal, or from 10 to 1000 kDal, or from 20 to 400 kDal, or from 20 to 300 kDal, or from 20 to 200 kDal, or from 20 to 100 kDal, or from 20 to 50 kDal, or from 40 to 300 kDal, or from 40 to 500 kDal, or from 20 to 600 kDal, or from 20 to 800 kDal, or from 20 to 1000 kDal. This polypeptide repeat unit also contains poly-alanine regions related to nanocrystalline regions, and glycine-rich regions related to beta-turn containing less-crystalline regions. In other embodiments the repeat is selected from any of the sequences listed as Seq ID Nos: 2-97.

[0056] In some embodiments, the quasi-repeat unit of the polypeptide can be described by the formula {GGY-[GPG-Xi] n i-GPS-(A)„2 } , where X 1 is independently selected from the group consisting of SGGQQ, GAGQQ, GQGPY, AGQQ and SQ, nl is a number from 4 to 8, and n2 is a number from 6 to 20. The repeat unit is composed of multiple quasi-repeat units. In additional embodiments, 3 "long" quasi repeats are followed by 3 "short" quasi-repeat units. As mentioned above, short quasi- repeat units are those in which nl=4 or 5. Long quasi- repeat units are defined as those in which nl=6, 7 or 8. In some embodiments, all of the short quasi-repeats have the same X 1 motifs in the same positions within each quasi-repeat unit of a repeat unit. In some embodiments, no more than 3 quasi-repeat units out of 6 share the same X 1 motifs.

[0057] In additional embodiments, a repeat unit is composed of quasi-repeat units that do not use the same X 1 more than two occurrences in a row within a repeat unit. In additional embodiments, a repeat unit is composed of quasi-repeat units where at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 of the quasi-repeats do not use the same Xi more than 2 times in a single quasi-repeat unit of the repeat unit.

[0058] In some embodiments, the structure of fibers formed from the described polypeptides form beta-sheet structures, beta-turn structures, or alpha-helix structures. In some

embodiments, the secondary, tertiary and quaternary protein structures of the formed fibers are described as having nanocrystalline beta-sheet regions, amorphous beta-turn regions, amorphous alpha helix regions, randomly spatially distributed nanocrystalline regions embedded in a non-crystalline matrix, or randomly oriented nanocrystalline regions embedded in a non-crystalline matrix.

[0059] In some embodiments, the polypeptides utilized to form fibers with mechanical properties as described herein include gly cine-rich regions from 20 to 100 amino acids long concatenated with poly-alanine regions from 4 to 20 amino acids long. In some

embodiments, polypeptides utilized to form fibers with good mechanical properties comprise 5-25% poly-alanine regions (from 4 to 20 poly-alanine residues). In some embodiments, polypeptides utilized to form fibers with good mechanical properties comprise 25-50% glycine. In some embodiments, polypeptides utilized to form fibers with good mechanical properties comprise 15-35% GGX, where X is any amino acid. In some embodiments, polypeptides utilized to form fibers with good mechanical properties comprise 15-60% GPG. In some embodiments, polypeptides utilized to form fibers with good mechanical properties comprise 10-40%) alanine. In some embodiments, polypeptides utilized to form fibers with good mechanical properties comprise 5-20%> proline. In some embodiments, polypeptides utilized to form fibers with good mechanical properties comprise 10-50%) beta-turns. In some embodiments, polypeptides utilized to form fibers with good mechanical properties comprise 10-50%) alpha-helix composition. In some embodiments all of these compositional ranges will apply to the same polypeptide. In some embodiments two or more of these

compositional ranges will apply to the same polypeptide. FIBER SPIN DOPE AND SPINNING PARAMETERS

[0060] In some embodiments, a spin dope is synthesized containing proteins expressed from any of the polypeptides of the present disclosure. The spin dope is prepared using published techniques such as those found in WO2015042164 A2. In some embodiments, a fiber spinning solution was prepared by dissolving the purified and dried block copolymer polypeptide in a formic acid-based spinning solution, using standard techniques. Spin dopes were incubated at 35 °C on a rotational shaker for three days with occasional mixing. After three days, the spin dopes were centrifuged at 16000 rcf for 60 minutes and allowed to equilibrate to room temperature for at least two hours prior to spinning.

[0061] In an embodiment the fraction of protein that is at least some percentage (e.g., 80%) of the intended length is determined through quantitative analysis of the results of a size- separation process. In an embodiment, the size-separation process can include size-exclusion chromatography. In an embodiment, the size-separation process can include gel

electrophoresis. The quantitative analysis can include determining the fraction of total protein falling within a designated size range by integrating the area of a chromatogram or densitometric scan peak. For example, if a sample is run through a size-separation process, and the relative areas under the peaks corresponding to full-length, 60% full-length and 20% full length are 3 :2: 1, then fraction that is full length corresponds to 3 parts out of a total of 6 parts = 50%.

[0062] In some embodiments, the proteins of the spin dope, expressed from any of the polypeptides of the present disclosure, are substantially monodisperse, with >5%, or >10%, or >15%, or >20%, or >25%, or >30%, or >35%, or >40%, or >45%, or >50%, or >55%, or >60%, or >65%, or >70%, or >75%, or >80%, or >85%, or >90%, or >95%, or >99% of the protein in the spin dope having molecular weight >5%, or >10%, or >15%, or >20%, or >25%, or >30%, or >35%, or >40%, or >45%, or >50%, or >55%, or >60%, or >65%, or >70%, or >75%, or >80%, or >85%, or >90%, or >95%, or >99% of the molecular weight of the encoded proteins. In some embodiments, the proteins of the spin dope, expressed from any of the polypeptides of the present disclosure, have from 5% to 99%, or from 5% to 50%, or from 50% to 99%, or from 20% to 80%, or from 40% to 60%, or from 5% to 30%, or from 70% to 99%, or from 5% to 20%, or from 5% to 10%, or from 80% to 99%, or from 90% to 99% of the protein in the spin dope having molecular weight from 5% to 99%, or from 5% to 50%, or from 50% to 99%, or from 20% to 80%, or from 40% to 60%, or from 5% to 30%, or from 70% to 99%, or from 5% to 20%, or from 5% to 10%, or from 80% to 99%, or from 90%) to 99% of the molecular weight of the encoded proteins. The "encoded proteins" are defined as the polypeptide amino acid sequences that are encoded by the DNA utilized in protein expression. In other words, the "encoded proteins" are the polypeptides that would be produced if there were no imperfect processes (e.g. transcription errors, protein degradation, homologous recombination, truncation, protein fragmentation, protein agglomeration) at any stage during protein production. A higher monodispersity of proteins in the spin dopes, in other words a higher purity, has the advantage of producing fibers with better mechanical properties, such as higher Young' s modulus, higher extensibility, higher ultimate tensile strength, and higher maximum tensile strength.

[0063] In one embodiment, 31% of the protein in the spin dope has molecular weight greater than 80%) of the proteins that were intended to be produced (i.e., the encoded proteins). In this case, 70%) of the proteins in the spin dope would be proteins other than the ones that were intended to be produced. One example of these other proteins are degraded protein fragments of the encoded proteins. Another example of these other proteins are foreign proteins that were not removed during any purification processes, such as proteins from the organisms being used to express the encoded proteins.

[0064] In other embodiments, fibers with low monodispersity, <5%, or <10%, or <15%, or <20%, or <25%, or <30%, or <35%, or <40%, or <45%, or <50%, or <55%, or <60%, or <65%, or <70%, or <75%, or <80%, or <85%, or <90%, or <95%, or <99% of the protein in the spin dope having molecular weight >5%, or >10%, or >15%, or >20%, or >25%, or >30%, or >35%, or >40%, or >45%, or >50%, or >55%, or >60%, or >65%, or >70%, or >75%, or >80%, or >85%, or >90%, or >95%, or >99% of the molecular weight of the proteins encoded by the DNA utilized in protein expression, were still able to create fibers with good mechanical properties. In other embodiments, fibers with low monodispersity, have from 5% to 99%, or from 5% to 50%, or from 5% to 30%, or from 10% to 50%, or from 20% to 50%, or from 50% to 99%, or from 20% to 80%, or from 40% to 60%, or from 5% to 30%, or from 70% to 99%, or from 5% to 20%, or from 5% to 10%, or from 80% to 99%, or from 90% to 99% of the protein in the spin dope having molecular weight 5% to 99%, or from 5% to 50%, or from 50% to 99%, or from 20% to 80%, or from 40% to 60%, or from 5% to 30%, or from 70% to 99%, or from 5% to 20%, or from 5% to 10%, or from 80% to 99%), or from 90% to 99% of the molecular weight of the proteins encoded by the DNA utilized in protein expression, were still able to create fibers with good mechanical properties. The mechanical properties described herein (e.g., high Young's (i.e., Elastic) modulus and/or extensibility (i.e., percent strain)), from fibers formed from low purity spin dopes was achieved through the use of the long polypeptide repeat units, suitable polypeptide

compositions and spin dope and fiber spinning parameters described elsewhere in the present disclosure.

[0065] In other embodiments, the proteins are produced via secretion from a microorganism such as Pichia pastoris, Escherichia coli, Bacillus subtilis, or mammalian cells. Optionally, the secretion rate is at least 20 mg /g DCW / hr (DCW = dry cell weight). Optionally, the proteins are then recovered, separated, and spun into fibers using spin dopes containing solvents. Some examples of the classes of solvents that can be used in spin dopes are aqueous, inorganic or organic, including but not limited to ethanol, methanol, isopropanol, t- butyl alcohol, ethyl acetate, and ethylene glycol. Various methods for synthesizing recombinant proteinaceous block copolymers have been published such as those found in WO2015042164 A2.

[0066] In other embodiments, the coagulation bath conditions for wet spinning are chosen to promote fiber formation with certain mechanical properties. Optionally, the coagulation bath is maintained at temperatures of 0-90° C, more preferably 20-60° C. Optionally, the coagulation bath comprises about 60%, 70%, 80%, 90%, or even 100% alcohol, preferably isopropanol, ethanol, or methanol. Optionally, the coagulation bath is 95:5%, 90: 10%, 85: 15%, 80:20%, 75:25%, 70:30%, 65:35%, 60:40%, 55:45% or 50:50% by volume methanol: water. Optionally, the coagulation bath contains additives to enhance the fiber mechanical properties, such as additives comprising ammonium sulfate, sodium chloride, sodium sulfate, or other protein precipitating salts at temperature from 20 to 60 °C.

[0067] In some embodiments, the extruded filament or fiber is passed through more than one bath. For embodiments in which more than one bath is used, the different baths have either different or same chemical compositions. In some embodiments, the extruded filament or fiber is passed through more than one coagulation bath. For embodiments in which more than one coagulation bath is used, the different coagulation baths have either different or same chemical compositions. The residence time can be tuned to improve mechanical properties, such as from 2 seconds to 100 minutes in the coagulant bath. The reeling/drawing rate can be tuned to improve fiber mechanical properties, such as a rate from 0.1 to 100 meters/minute.

[0068] The draw ratio can also be tuned to improve fiber mechanical properties. In different embodiments the draw ratio was 1.5X to 30X. In one embodiment, lower draw ratios improved the fiber extensibility. In one embodiment, higher draw ratios improved the fiber maximum tensile strength. Drawing can also be done in different environments, such as in solution, in humid air, or at elevated temperatures. [0069] The fibers of the present disclosure processed with residence times in coagulation baths at the longer end of the disclosed range produce corrugated cross sections, as shown in FIG. 3. That is, each fiber has a plurality of corrugations (or alternatively "grooves") disposed at an outer surface of a fiber. Each of these corrugations is parallel to a longitudinal axis of the corresponding fiber on which the corrugations are disposed. The fibers of the present disclosure processed with higher ethanol content in the coagulation bath produce hollow core fibers, as shown in FIG. 2. That is, the fiber includes an inner surface and an outer surface. The inner surface defines a hollow core parallel to the longitudinal axis of the fiber.

[0070] In some embodiments a coagulation bath or the first coagulation bath is prepared using combinations of one or more of water, acids, solvents and salts, including but not limited to the following classes of chemicals of Bransted-Lowry acids, Lewis acids, binary hydride acids, organic acids, metal cation acids, organic solvents, inorganic solvents, alkali metal salts, and alkaline earth metal salts. Some examples of acids used in the preparation of a coagulation bath or the first coagulation bath are dilute hydrochloric acid, dilute sulfuric acid, formic acid and acetic acid. Some examples of solvents that are used in the preparation of the first coagulation bath are ethanol, methanol, isopropanol, t-butyl alcohol, ethyl acetate, and ethylene glycol. Examples of salts used in the preparation of a coagulation bath or the first coagulation bath include LiCl, KC1, BeC12, MgC12, CaC12, NaCl, ammonium sulfate, sodium sulfate, and other salts of nitrates, sulfates or phosphates.

[0071] In some embodiments, the chemical composition and extrusion parameters of a coagulation bath or the first coagulation bath are chosen so that the fiber remains translucent in a coagulation bath or the first coagulation bath. In some embodiments the chemical composition and extrusion parameters of a coagulation bath or the first coagulation bath are chosen to slow down the rate of coagulation of the fiber in a coagulation bath or the first coagulation bath, which improves the ability to draw the resulting fiber in subsequent drawing steps. In various embodiments, these subsequent drawing steps are done in different environments, including wet, dry, and humid air environments. Examples of wet

environments include one or more additional baths or coagulation baths. In some

embodiments, the fiber travels through one or more baths after the first coagulation bath. The one or more additional baths, or coagulation baths, are prepared, in embodiments, using combinations of one or more of water, acids, solvents and salts, including but not limited to the following classes of chemicals of Bransted-Lowry acids, Lewis acids, binary hydride acids, organic acids, metal cation acids, organic solvents, inorganic solvents, alkali metal salts, and alkaline earth metal salts. Some examples of acids that are used in the preparation of the second baths or coagulant baths are dilute hydrochloric acid, dilute sulfuric acid, formic acid and acetic acid. Some examples of solvents that are used in the preparation of the second coagulant baths are ethanol, methanol, isopropanol, t-butyl alcohol, ethyl acetate, and ethylene glycol. Some examples of salts used in the preparation of a second bath or coagulation bath include LiCl, KC1, MgC12, CaC12, NaCl, ammonium sulfate, sodium sulfate, and other salts of nitrates, sulfates, or phosphates. In some embodiments, there are two coagulation baths, where the first coagulation bath has a different chemical composition than the second coagulation bath, and the second coagulation bath has a higher concentration of solvents than the first coagulation bath. In some embodiments, there are more than two coagulation baths, and the first coagulation bath has a different chemical composition than the second coagulation bath, and the second coagulation bath has a lower concentration of solvents than the first coagulation bath. In some embodiments, there are two baths, the first being a coagulation bath and the second being a wash bath. In some embodiments, the first coagulation bath has a different chemical composition than the second wash bath, and the second wash bath has a higher concentration of solvents than the first bath. In some embodiments, there are more than two baths, and the first bath has a different chemical composition than the second bath, and the second bath has a lower concentration of solvents than the first bath.

[0072] In some embodiments a spin dope is further prepared using combinations of one or more of water, acids, solvents and salts, including but not limited to the following classes of chemicals of Bransted-Lowry acids, Lewis acids, binary hydride acids, organic acids, metal cation acids, organic solvents, inorganic solvents, alkali metal salts, and alkaline earth metal salts. Some examples of acids that are used in the preparation of spin dopes are dilute hydrochloric acid, dilute sulfuric acid, formic acid and acetic acid. Some examples of solvents that are used in the preparation of spin dopes are ethanol, methanol, isopropanol, t- butyl alcohol, ethyl acetate, and ethylene glycol. Some examples of salts that are used in the preparation of spin dopes are LiCl, KC1, MgC12, CaC12, NaCl, ammonium sulfate, sodium sulfate, and other salts of nitrates, sulfates or phosphates.

[0073] In some embodiments, a spinneret is chosen to enhance the fiber mechanical properties. The dimensions of the spinneret can be from 0.001 cm to 5 cm long, and from 25 to 35 gauge. In some embodiments, a spinneret includes multiple orifices to spin multiple fibers simultaneously. In some embodiments, the cross-section of a spinneret gradually tapers to the smallest diameter at the orifice, is straight-walled and then quickly tapers to the orifice, or includes multiple constrictions. An extrusion pressure of a spin dope from a spinneret can also be varied to affect the fiber mechanical properties in a range from 10 to 1000 psi. The interaction between fiber properties and extrusion pressure can be affected by spin dope viscosity, drawing/reeling rate, and coagulation bath chemistry.

[0074] The concentration of protein to solvent in the spin dope is also an important parameter. In some embodiments, the concentration of protein weight for weight is 20%, or 25%, or 30%, or 35%, or 40%, or 45% or 50%, or 55%, or from 20% to 55%, or from 20% to 40%, or from 30% to 40%, or from 30% to 55%, or from 30% to 50% in solution with solvents and other additives making up the remainder. EXAMPLE 1 : FIBER SPINNING

[0075] Copolymers of the present disclosure were secreted from Pichia pastoris commonly used for the expression of recombinant DNA using published techniques, such as those described in WO2015042164 A2. In some embodiments, a secretion rate of at least 20 mg /g DCW / hr (DCW = dry cell weight) was observed. The secreted proteins were purified, dried, and dissolved in a formic acid-based spinning solvent, using standard techniques, to generate a homogenous spin dope.

[0076] The spin dope was extruded through a 50-200 μπι diameter orifice with 2: 1 ratio of length to diameter into a room temperature alcohol-based coagulation bath comprising 20% formic acid with a residence time of 28 seconds. Fibers were pulled out of the coagulation bath under tension, strung through a wash bath consisting of 100%) alcohol drawn to 4 times their length, and subsequently allowed to dry.

EXAMPLE 2: FIBER CROSS-SECTION

[0077] Using the above synthesis methods, morphology of extruded fibers was varied by adjusting various parameters of a coagulation bath. For example, hollow core fibers (as shown in FIG. 2) were synthesized by having a higher ethanol content of the coagulation bath, as described above. In another example, corrugated morphologies (as shown in FIG. 3) were produced by increasing residence time in a coagulation bath to in the range of 2 - 100 seconds.

[0078] The fibers of the present disclosure processed with residence times in coagulation baths at the longer end of the disclosed range tend to show corrugated cross-sections, as shown in FIG. 3 and as described above.

[0079] Fibers of the present disclosure processed with higher ethanol content in a coagulation bath include hollow cores, as shown in FIG. 2 and described above.

EXAMPLE 3 : FIBER MECHANICAL PROPERTIES [0080] FIGS. 4A - 4D and FIGS. 5-7 show various mechanical properties of measured samples, with the compositions described herein, and produced by the methods described herein.

[0081] Some of the mechanical properties of the fibers in this disclosure are reported in units of MPa (i.e. 10 6 N/m 2 , or force per unit area), and some are reported in units of cN/tex (force per linear density). The measurements of fibers mechanical properties reported in MPa were obtained using a custom instrument, which includes a linear actuator and calibrated load cell, and the fiber diameter was measured by light microscopy. The measurements of fibers mechanical properties reported in cN/tex were obtained using FAVEVIAT testing equipment, which includes a measurement of the fiber linear density using a vibration method (e.g.

according to ASTM D1577). To accurately convert measurements from MPa to cN/tex, an estimate of the bulk density (e.g. in g/cm 3 ) of the fiber is used. An expression that can be used to convert a force per unit area in MPa, "FA", to a force per linear density in cN/tex, "FLD", using the bulk density in g/cm 3 , "BD", is FLD = FA/(10*BD). Since the bulk density of recombinant silk can vary, a given value of fiber tenacity in MPa does not translate to a given value of fiber tenacity in cN/tex. However, if the bulk density of the recombinant silk is assumed to be from 1.1 to 1.4 g/cm 3 , then mechanical property values can be converted from one set of units into the other within a certain range of error. For example, a maximum tensile stress of 100 MPa is equivalent to about 9.1 cN/tex if the mass density of the fiber is 1.1 g/cm 3 , and a maximum tensile stress of 100 MPa is equivalent to about 7.1 cN/tex if the mass density of the fiber is 1.4 g/cm 3 .

[0082] A set of 4 fibers was tested for tensile mechanical properties using an instrument including a linear actuator and calibrated load cell, the results of which are shown in FIG. 4A. Fibers were pulled at 1% per second strain rate until failure. Fiber diameters were measured with light microscopy at 20x magnification using image processing software. The mean diameter was 10.25 um, +/- 1 st.dev = 6.4 - 14.1 um. The mean max tensile stress was 97.9 MPa, +/- 1 st.dev = 68.1 - 127.6 MPa. The mean max strain was 37.2%, +/- 1 st.dev = -11.9 - 86.3%. The mean yield stress was 87.4 MPa, +/- 1 st.dev = 59.2 - 115.6 MPa. The mean initial modulus (same as elastic modulus, same as Young's modulus) was 5.2 GPa, +/- 1 st.dev = 3.5 - 6.9 GPa.

[0083] As shown in FIG. 4B, set of 7 fibers was tested for tensile mechanical properties using an instrument including a linear actuator and calibrated load cell. Fibers were pulled at 1% per second strain rate until failure. Fiber diameters were measured with light microscopy at 20x magnification using image processing software. The mean diameter was 6.2 um, +/- 1 st.dev = 4.9 - 7.5 um. The mean max tensile stress was 127.9 MPa, +/- 1 st.dev = 106.4 - 149.3 MPa. The mean max strain was 105.5%, +/- 1 st.dev = 61.0 - 150.0%. The mean yield stress was 109.8 MPa, +/- 1 st.dev = 91.4 - 128.2 MPa. The mean initial modulus (same as elastic modulus, same as Young's modulus) was 5.5 GPa, +/- 1 st.dev = 4.4 - 6.6 GPa.

[0084] As shown in FIG. 4C, a set of 4 fibers was tested for tensile mechanical properties using an instrument including a linear actuator and calibrated load cell. Fibers were pulled at 1%) per second strain rate until failure. Fiber diameters were measured with light microscopy at 20x magnification using image processing software. The mean diameter was 8.9 um, +/- 1 st.dev = 6.9 - 11.0 um. The mean max tensile stress was 93.2 MPa, +/- 1 st.dev = 81.4 - 105.0 MPa. The mean max strain was 128.9%, +/- 1 st.dev = 84.0 - 173.8%. The mean yield stress was 83.3 MPa, +/- 1 st.dev = 64.9 - 101.7 MPa. The mean initial modulus (same as elastic modulus, same as Young's modulus) was 2.6 GPa, +/- 1 st.dev = 1.5 - 3.8 GPa.

[0085] FIG. 4D shows a stress strain curve of fibers of the present disclosure in which maximum tensile stress is greater than 100 MPa, maximum tensile stress is from 111 MPa to 130 MPa, initial elastic modulus (i.e. Young's modulus) is from 6 GPa to 7.1 GPa, maximum strain (i.e. extensibility) is from 18% to 111%, and the yield stress is from 107 MPa to 112 MPa. The ultimate tensile stress is also greater than 100 MPa for one of the fibers in this figure. [0086] While not wishing to be bound by theory, the structural properties of the proteins within the spider silk are theorized to be related to fiber mechanical properties. Crystalline regions in a fiber have been linked with the tensile strength of a fiber, while the amorphous regions have been linked to the extensibility of a fiber. The major ampullate (MA) silks tend to have higher strengths and less extensibility than the flagelliform silks, and likewise the MA silks have higher volume fraction of crystalline regions compared with flagelliform silks. Furthermore, theoretical models based on the molecular dynamics of crystalline and amorphous regions of spider silk proteins, support the assertion that the crystalline regions have been linked with the tensile strength of a fiber, while the amorphous regions have been linked to the extensibility of a fiber. Additionally, the theoretical modeling supports the importance of the secondary, tertiary and quaternary structure on the mechanical properties of recombinant protein fibers. For instance, both the assembly of nano-crystal domains in a random, parallel and serial spatial distributions, and the strength of the interaction forces between entangled chains within the amorphous regions, and between the amorphous regions and the nano-crystalline regions, influenced the theoretical mechanical properties of the resulting fibers.

[0087] A set of the fibers described herein was tested for tensile mechanical properties using an instrument including a linear actuator and calibrated load cell. Fibers were pulled at 1% per second strain rate until failure. Fiber diameters were measured with light microscopy at 20x magnification using image processing software. The mean maximum stress ranged from 24-172 MPa. The mean maximum strain ranged from 2-342% (see FIG. 5, for example). The mean initial modulus ranged from 1617-7040 MPa (see Figure 6). The average toughness of three fibers was measured at 0.5 MJ m-3 (standard deviation of 0.2), 20 MJ m-3 (standard deviation of 0.9), and 59.2 MJ m-3 (standard deviation of 8.9). The diameters ranged from 4.48-12.7 μπι. Some of the fibers cross-sections were processed to be circular with smooth surfaces, some with a hollow core, and some with rough corrugated surfaces described as corrugated (FIGS. 2 and 3, respectively).

[0088] FIG. 7 shows stress strain curves of 23 fibers of the present disclosure, which includes fibers with maximum tensile stress greater than 20 cN/tex, and the average of the maximum tensile stresses of the 23 fibers is about 18.6 cN/tex. The maximum tensile stress ranges from about 17 to 21 cN/tex, and the standard deviation of the maximum tensile stress in this example is about 1.0 cN/tex. The average initial elastic modulus (i.e. Young's modulus) of the 23 fibers is about 575 cN/tex, and the standard deviation in this example is about 6.7 cN/tex. The average maximum elongation of the 23 fibers is about 10.2%, and the standard deviation in this example is about 3.6%. The average work of rupture (a measure of toughness) of the 23 fibers is about 0.92 cN*cm, and the standard deviation in this example is about 0.43 cN*cm. The average linear density of the 23 fibers is about 3.1 dtex, and the standard deviation in this example is about 0.11 dtex.

ADDITIONAL CONSIDERATIONS

[0089] The foregoing description of the embodiments of the disclosure has been presented for the purpose of illustration; it is not intended to be exhaustive or to limit the claims to the precise forms disclosed. Persons skilled in the relevant art can appreciate that many modifications and variations are possible in light of the above disclosure.

[0090] The language used in the specification has been principally selected for readability and instructional purposes, and it may not have been selected to delineate or circumscribe the inventive subject matter. It is therefore intended that the scope of the disclosure be limited not by this detailed description, but rather by any claims that issue on an application based hereon. Accordingly, the disclosure of the embodiments is intended to be illustrative, but not limiting, of the scope of the invention, which is set forth in the following claims.